Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 4/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.33 |
| ▸ | TPO | P07202 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23218012 | 0.81 | MPO (0.55) | MPOOPRM1TPOALDH1A1CYP1A2 | |
| SCHEMBL27103046 | 0.80 | MPO (0.54) | MPOOPRM1TPOALDH1A1CYP1A2 | |
| SCHEMBL23225714 | 0.77 | OPRM1 (0.48) | MPOOPRM1 | |
| SCHEMBL29773063 | 0.74 | OPRM1 (0.45) | MPOOPRM1ALDH1A1PLK1 | |
| Verdiperstat SCHEMBL1536607 | 0.72 | MPO (1.00) | MPOOPRM1TPO | |
| SCHEMBL23225611 | 0.68 | MPO (0.52) | MPOOPRM1HPRT1ALDH1A1CYP1A2 | |
| Verdiperstat SCHEMBL23225670 | 0.66 | MPO (0.58) | MPOOPRM1TPOALDH1A1CYP1A2 | |
| SCHEMBL29879357 | 0.65 | MPO (0.70) | MPOOPRM1TPO | |
| SCHEMBL23225606 | 0.65 | OPRM1 (0.36) | MPOOPRM1 | |
| SCHEMBL29879737 | 0.63 | OPRM1 (0.32) | MPOOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| WO-2021072140-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | MPO, CAT, SOD1 | MPO 1/4885OPRM1 1161/4885HPRT1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.